BMS-986142

BMS-986142 is a potent and highly selective reversible small molecule inhibitor of BTK with an IC50 of 0.5 nM. In a panel of 384 kinases, only five kinases were inhibited by BMS-986142 with less than 100-fold selectivity for BTK (TEC, ITK, BLK, TXK and BMX).

BMS-986142化学構造

CAS No. 1643368-58-4

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫なし(納期7~10日)
JPY 68500 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(1)

製品安全説明書

現在のバッチを見る: S838101 DMSO] 100 mg/mL] false] Water] Insoluble] false] Ethanol] Insoluble] false 純度: 99.76%
99.76

BMS-986142関連製品

シグナル伝達経路

BTK阻害剤の選択性比較

生物活性

製品説明 BMS-986142 is a potent and highly selective reversible small molecule inhibitor of BTK with an IC50 of 0.5 nM. In a panel of 384 kinases, only five kinases were inhibited by BMS-986142 with less than 100-fold selectivity for BTK (TEC, ITK, BLK, TXK and BMX).
Targets
BTK [1]
(Cell-free assay)
0.5 nM
In Vitro
In vitro

In B cells stimulated through the B cell receptor (BCR), BMS-986142 potently inhibits signaling and functional end points, including calcium flux (IC50 = 9 nM), production of cytokines, proliferation, and surface expression of the costimulatory molecule CD86 (IC50 = 3−4 nM). In T cells, ITK-catalyzed phosphorylation of PLCγ1 stimulated through the T cell receptor (TCR) is at least 45-fold less potently inhibited by BMS-986142 than BTK-dependent signaling end points in B cells, as expected based on the 30-fold selectivity for BTK over ITK in the enzymatic assays[2].

Kinase Assay Human Recombinant BTK Enzyme Assay
To V-bottom 384-well plates were added test compounds, human recombinant BTK (1 nM), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES at pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant, and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to control reactions with no enzyme (for 100% inhibition) and controls with no inhibitor (for 0% inhibition). Dose−response curves were generated to determine the concentration required for inhibiting 50% of BTK activity (IC50). Compounds were dissolved at 10 mM in DMSO and evaluated at 11 concentrations.
細胞実験 細胞株 Ramos B cells
濃度 0.4, 1.6, 6, 25, 100 and 400 nM
反応時間 1 h
実験の流れ

B-cell receptor (BCR)-stimulated phospholipase C (PLC)-γ2 phosphorylation in Ramos B cells: After 1 hour of pre-incubation of Ramos B cells in media containing 10% fetal bovine serum (FBS) with varying concentrations of BMS-986142 at 37°C, the cells are stimulated with AffiniPure F(ab’)2 fragment goat anti-human immunoglobulin (Ig)M at 50 μg/mL for exactly 2 minutes at 37°C, followed by addition of ice-cold phosphate-buffered saline for quenching. The cells are pelleted and lysed, and PLCγ2 levels are measured by immunoblot using rabbit anti-human phosphoY759-PLCγ2 and analyzed using the Odyssey Infrared Imaging System with normalization to an actin control to ensure consistent loading.

In Vivo
In Vivo

In multispecies pharmacokinetic studies, the absolute oral bioavailability of BMS-986142 is 93% in mice, 67% in rats, 33% in cynomolgus monkeys, and 100% in dogs. The total body plasma clearance of BMS-986142 is low in all species. The large steady-state volume of distribution observed is indicative of extravascular distribution, in spite of the high protein binding. However, brain penetration is very low in rats (<5% of plasma concentration). BMS-986142 blocks the increase in severe proteinuria in a female NZB/W lupus-prone mouse model in vivo. Treatment with BMS-986142 provides robust protection against tubulo-interstitial and glomerular nephritis, as well as inflammatory infiltration[2].

動物実験 動物モデル female NZB/W lupus-prone mouse model
投与量 30 mg/kg
投与経路 by oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02638948 Completed
Rheumatoid Arthritis
Bristol-Myers Squibb
February 16 2016 Phase 2
NCT02257151 Completed
Healthy Adult
Bristol-Myers Squibb
September 2014 Phase 1

化学情報

分子量 572.60 化学式

C32H30F2N4O4

CAS No. 1643368-58-4 SDF --
Smiles CC1=C(C=CC=C1N2C(=O)C3=C(C(=CC=C3)F)N(C2=O)C)C4=C(C=C(C5=C4C6=C(N5)CC(CC6)C(C)(C)O)C(=O)N)F
保管 3 years -20°C powder

In vitro
Batch:

DMSO : 100 mg/mL ( (174.64 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: BMS-986142を買う | BMS-986142 ic50 | BMS-986142供給者 | BMS-986142を購入する | BMS-986142費用 | BMS-986142生産者 | オーダーBMS-986142 | BMS-986142化学構造 | BMS-986142分子量 | BMS-986142代理店